PowerShares DWA Healthcare Momentum ETF

In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.

PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.

MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.

Momentum stocks are only affected by a significant rise or fall of the VIX, unlike minimum volatility stocks, which are affected by even a minor change in the VIX.

The PowerShares DWA Healthcare Momentum Portfolio (PTH) invests 4.54% of its holdings in Cooper.

Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

The five-year annualized return of PTH is 21.0%. SPY comes in 15.75%. Clearly, PTH’s smart beta strategy has outperformed the market.

Top holdings for PTH include Regeneron Pharmaceuticals (REGN), Allergan (AGN), Cigna (CI), Incyte (INCY), and Medivation (MDVN).

The performance of PTH tracks more closely to PBE than PJP.

PTH seeks to mimic the investment results of the Dorsey Wright Healthcare Technical Leaders Index, selecting stocks based on their momentum.